Accounting for 20–30% of all RP cases and with more than 150 dominant mutations described, autosomal dominant retinitis pigmentosa (adRP), due to RHODOPSIN gene (RHO-AdRP, RP4 (OMIM: 613731)) [8,9], has become a prominent disease model to assess the effects of Rho targeted and Rho mutation independent approaches [10]. The gene discussed is PLIN2; the disease is autosomal dominant retinitis pigmentosa.